Imexpharm Corporation (HOSE:IMP)

Market Cap	7.82T +20.4%
Revenue (ttm)	2.39T +3.7%
Net Income	311.12B +7.0%
EPS	2,020.16 +8.6%
Shares Out	154.01M
PE Ratio	25.15
Forward PE	21.31
Dividend	500.00 (0.98%)
Ex-Dividend Date	Jun 9, 2025

Volume	31,355
Average Volume	40,211
Open	47,000
Previous Close	47,500
Day's Range	46,600 - 50,800
52-Week Range	42,800 - 57,000
Beta	0.46
RSI	37.90
Earnings Date	Jul 17, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietna...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 1,444
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 10.34%.